Mid-Term Business Plan (FY9/2020-9/2024) Medium-term Business Plan

　 　

Theme

Behavioral Guideline
即今・当処・自己
Do it now, here, by yourself
When do you do it if you don't do it now?
Where do you do it if you don't do it here?
Who does it if you don't do it?

In the Mid-Term Business Plan, under the slogan of "Fuji-rashiku wo Atarashiku (Evolving Fuji)", Fuji Pharma will reinforce its areas of strengths, aggressively enter into new areas. It also enhances its pipeline so that Fuji Pharma can further grow over the next five years, while at the same time considering marketing methods which fit the new era.

　 　

Positioning of the Mid-Term Business Plan (FY9/2020-9/2024)

The Mid-Term Business Plan is a concrete embodiment of its strategy for the first 5 years of the Vision for 2030, "where we are in 10 Years from Now."

Figure

* NGT: New Generation Technology

　 　

Basic Policy

As a growth scenario in the Mid-Term Business Plan, Fuji Pharma defined growth scenarios as women's healthcare field, biosimilar business, overseas business, contrast media business, and 9 strategies to execute these scenarios.

Growth Strategy Strategy Target in 9/2029
Category
x
Modality		 ①Women's Healthcare
  • No.1 in WH platform
  • New product launches (mainly hormone)
  • Contribute to women's well-being not only by drugs
  • Digitalization
②Injection
  • CM new business model is established
  • Build globally competitive injectable production line
③Hormone
  • Large quantity multi-product manufacturing system is built
  • Men's hormones, anti-cancer, and other products
④NGT
  • Difficult-to-make technology is established
⑤Biosimilar
  • No.1 in Japan BS market
  • Multiple Alvotech products launched
Area ⑥Asia
  • Sustainable CMO growth in OLIC
  • S&M launched in China and ASEAN
⑦N. America
  • 505(b)(2) launched by Fuji Pharma USA
HR ⑧Human Resources
  • Diversified executive officer team
  • Training programs successfully operated
  • Language skills improved
Sustainability ⑨Sustainability
  • "Integrating the world happiest company and social contribution"

* OLIC: Fuji's subsidiary CMO company (Head office and plant in Thailand)

Women's Healthcare

In addition to the launch of new products centering on new drugs for women's healthcare, Fuji Pharma also contributes to enhancing women's well-being with services in non-drug peripheral areas. Fuji Pharma also aims to become the No. 1 company in women's healthcare by promoting digitalization and providing value efficiently and effectively.

Figure

Biosimilar

With the aim of becoming No. 1 in biosimilar business in Japan in the long term, Fuji Pharma will expand its product portfolio through collaboration with Alvotech and build a business promotion and sales structure under the Mid-Term Business Plan. In addition, Fuji Pharma will develop high value-added formulations.

Figure

Overseas

Fuji Pharma will take on the challenge of growing CMO business in Asia and Sales & Marketing business centered on FSN-013, a new drug for women's healthcare, with its group company, OLIC. In addition, it will build on the 505(b)(2) products to expand business in the new area of North America.

Figure

* 505(b)(2) product: An application that contains full reports of investigations of safety and effectiveness but where at least some of the information required for approval comes from studies not conducted by or for the applicant and for which the applicant has not obtained a right of reference

Contrast Media

In order to enhance sustainability of the contrast media business, which has the largest market share and is one of Fuji Pharma's core businesses, and to ensure a stable supply of contrast medias to the medical community, Fuji Pharma will take on the challenge of building a sustainable new business model for contrast medias under the Mid-Term Business Plan.

Figure

Human Resources

Since its establishment, Fuji Pharma has strived to develop its employees in its belief that "Put People First" underlying its Management Philosophy, "Our corporate growth is proportional to our personal growth." The Mid-Term Business Plan has 3 pillars: Diversity, Next-generation management, and Global talents development, as Fuji Pharma further focuses on developing the employees who will carry the future of Fuji Pharma.

Figure

Sustainability

Fuji Pharma aims to achieve its goal of "Integrating the world's happiest company with social contribution" by implementing company-wide sustainability activities.

Figure

* Seven core topics: (1) Organizational governance, (2) Human rights, (3) Labor practices, (4) Environment, (5) Fair business practices, (6) Consumer issues, and (7) Community participation and development

　 　

Financial Target

In FY 9/2024, the last fiscal year of the Mid-Term Business Plan, Fuji Pharma aims to achieve net sales of 50 billion yen, operating profit of 5 billion yen, and return on equity (ROE) of 8.0%.

Figure 1

* Total amount during MTP

Figure 2 　 　

Shareholder Return Policy

Fuji Pharma considers it essential to maintain and further enhance shareholder return. In deciding the allocation of profits, Fuji Pharma comprehensively takes into account current net profit, future business performance trends, and internal reserves for the future business development, among other things. While continuing to invest to provide value, Fuji Pharma aims to achieve 30% payout ratio with stable dividends.
In addition to dividends, Fuji Pharma considers share repurchase as one of shareholder return options. For the time being, however, Fuji Pharma intends to allocate funds for strategic investments in line with the implementation of its growth strategy.

Figure
  • ・On July 1, 2018, one common stock was split into 2 stocks. Dividend per share assumes current total outstanding shares.
  • ・9/2020E payout ratio is estimate at the beginning of fiscal year.
Please see for the presentation materials.